Korean Chinese Japanese
  • Economy
  • Politics
  • Society
  • Securities
  • Real estate
  • Culture
  • Entertainment
  • Sports
  • Opinion
Korean Chinese Japanese
Economy Corporation Pharma & Bio
Society Politics IT·Science
Securities Real Estate Global
Opinion Entertainment Sports Culture
Video Auto in Golf in
PHARM EDAILY Market in TheBeLT
Pharma & Bio
Technology

Competitor Drug Faces Challenges in Confirmatory Clinical Trials, HLB INC.’s Ripictu Receives Full Approval… Background on the FDA’s Decision

Few people know the U.S. Food and Drug Administration (FDA) approval process for “Ripicto” (generic name: lirapugratinib) as thoroughly as Jang Seong-hun, former vice president of Eleva Therapeutics. …
  • 2026-10-02 08:07:02
  • KIM SAE-MI
Lifestyle

[Exclusive] Remedy Selects Indonesia as Its Southeast Asian Hub… Sets Out to Establish a Local Production System

#Remedy, a company specializing in medical imaging and artificial intelligence (AI), has designated Indonesia as its key strategic base for targeting the Southeast Asian public healthcare market. The …
  • 2026-10-02 07:02:02
  • YU JIN-HEE
Technology

Helixmith and Genome & Company Surge on Royalty News [K-bio pulse]

Korean pharmaceutical, biotech, and healthcare stocks linked to drug commercialization and licensing prospects rallied on September 30.Helixmith rose nearly 20% on expectations of royalties from its C…
  • 2026-10-02 06:07:03
  • Kim Seung-kwon
Technology

[Bio Spotlight] Gaining Momentum from 'Royalties, Technology Transfers, and Exclusive Rights'… Helixmith Co., Ltd and Genome&Company Soar

On the 30th, Helixmith Co., Ltd(084990)rose nearly 20% on expectations of royalties from the commercialization of a gene therapy by its Chinese partner, while Genome&Company(314130)posted double-digit…
  • 2026-10-02 06:07:02
  • Kim Seung-kwon
Technology

Peptron, Inc.: Two Years Waiting for Lilly’s Response… Anticipation for Follow-up DDS Contract and Clinical Trial Announcements [Bio Monthly Roundup]

In October, the focus of the domestic pharmaceutical and biotech market is expected to shift to follow-up contracts by drug delivery system (DDS) companies and clinical results to be presented at glob…
  • 2026-10-02 06:01:02
  • NA EUN-KYUNG
Technology

Two Doses of ‘APB-R3’ Provide 12-Week Effect… AprilBio Co.,Ltd. ‘SAFA’ Offers a Glimmer of Hope

AprilBio Co.,Ltd.(397030)The atopic dermatitis treatment “EVO301” (APB-R3), which Safa (SAFA) licensed to U.S.-based Evomune, has reaffirmed its efficacy in a Phase 2a clinical trial and is moving on …
  • 2026-10-02 06:01:01
  • KIM SAE-MI
Lifestyle

SG Bio Shakes Off Its ‘Seegene Captive’ Status… Achieves ‘7:3’ Golden Ratio in Revenue Structure

SG BioScience (formerly SG CO., LTD.; hereinafter “SG Bio”), a company specializing in in vitro diagnostics, is significantly reducing its “reliance on Seegene Inc.,” which has long been identified as…
  • 2026-10-01 08:06:03
  • YU JIN-HEE
Technology

Returned After 2 Years and 8 Months of Development Halt… The Importance of Rights Reclamation Highlighted by HanmiPharm’s ‘Belbarafenib’

HanmiPharm(128940)The company is set to regain the overseas rights to “Belvarapenib,” an anti-cancer candidate compound it licensed to U.S.-based Genentech 10 years ago. Although Genentech officially …
  • 2026-10-01 08:01:02
  • NA EUN-KYUNG
Technology

Beyond Technology Exports to Licensing and Sales… HLB INC.’s ‘Ripictu’ Blazes a New Trail for K-Bio

HLB INC.(028300)has cleared the U.S. Food and Drug Administration (FDA) hurdle for the first time. This comes after the company had suffered three consecutive setbacks with its new liver cancer drug, …
  • 2026-10-01 07:01:02
  • KIM SAE-MI
Technology

AriBio Holdings Hits Lower Limit After Scrapping Merger With AriBio [K-bio bulse]

Korean pharmaceutical, biotech, and healthcare stocks showed sharply mixed movements on September 29 as company-specific news drove trading. AriBio Holdings plunged to its daily lower limit in after-h…
  • 2026-10-01 06:42:01
  • Kim Seung-kwon
prev 11 12 13 14 15 16 17 18 19 20 next

PHARM EDAILY

Shorts

EDAILY
  • 92, Tongil-ro, Jung-gu, Seoul, Korea
  • +82 2 3772 0114
  • webmaster@edaily.co.kr

※ This article has been translated using AI technology for the convenience of readers.

EDAILY provides this translation on an “as is” basis and makes no warranties, express or implied, regarding its accuracy, reliability, completeness, merchantability, or fitness for a particular purpose.
Due to the limitations of machine translation, the translated content may differ from the original Korean article. In the event of any discrepancy, the original Korean version shall prevail.
EDAILY shall not be liable for any loss or damage arising from the use of, or reliance on, the translated content.

© 2026 Copyrights by edaily. All Rights Reserved.
Korea China Japan
English